Stock Price, News, Quote and Profile of PSYENCE BIOMEDICAL LTD(NASDAQ:PBM) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PSYENCE BIOMEDICAL LTD

NASDAQ:PBM (5/31/2024, 7:00:02 PM)

After market: 0.78 +0.03 (+4%)

0.75

+0.02 (+2.04%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorN/A

GICS IndustryN/A

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 MonthN/A

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap10.04M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Company Profile

Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Company Info

PSYENCE BIOMEDICAL LTD

121 Richmond Street West Penthouse, Suite 1300

TORONTO ONTARIO V6E 3Z3

P: 17744604171

CEO: John Plourde

Employees: 0

Website: http://psyence.com

PBM News

15 days ago - Psyence Biomedical Ltd.Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will...

2 months ago - Psyence Group Inc.Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (

2 months ago - Psyence Biomedical Ltd.Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian...

2 months ago - Psyence Group Inc.Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc (

2 months ago - Psyence Biomedical Ltd.Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic...

3 months ago - Psyence Biomedical Ltd.Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two...

PSYENCE BIOMEDICAL LTD (PBM)

Nasdaq Stock Screener

USA Stock Screener

Technical Stock Screener

Fundamental Stock Screener

Company Profile

Company Info

PBM News

PBM Twits